KIMSKrishna Institute of Medical Sciences Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on KIMS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 34/100)
- • Profit growth: -46.9% YoY
- • ROE: 10.7%
- • RSI: 28
- • MACD: bearish
Bull case
- • Revenue growth: 35.3% YoY
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 41
- • 6-month vs NIFTY: +6.3% relative
Bear case
- • Profit growth: -46.9% YoY
- • ROE: 10.7%
- • RSI: 28
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Profit growth: -46.9% YoY
- • ROE: 10.7%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹20.81). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.